XML 65 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash flows from operating activities:    
Net income $ 2,058,980 $ 1,405,035
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation and amortization 530,508 373,357
Share-based compensation 119,508 104,851
Deferred income taxes (229,273) (166,187)
Other (95,711) (36,577)
Changes in operating assets and liabilities, net:    
Accounts receivable (297,057) (219,860)
Inventory (119,890) (182,814)
Accrued expenses and other current liabilities 19,283 110,794
Other changes in operating assets and liabilities, net 22,904 87,474
Net cash flows provided by operating activities 2,009,252 1,476,073
Cash flows from investing activities:    
Proceeds from sales and maturities of marketable securities 1,942,871 5,025,218
Purchases of marketable securities (2,738,584) (2,473,609)
Acquisition of TYSABRI rights 0 (3,262,719)
Purchases of property, plant and equipment (180,854) (167,628)
Contingent consideration related to Fumapharm AG acquisition (175,000) 0
Other (13,131) (15,954)
Net cash flows used in investing activities (1,164,698) (894,692)
Cash flows from financing activities:    
Purchase of treasury stock (359,981) (400,308)
Proceeds from issuance of stock for share-based compensation arrangements 44,960 56,367
Repayment of borrowings under senior notes and other debt (2,674) (452,340)
Excess tax benefit from stock options 90,423 67,902
Other (15,336) 670
Net cash flows used in financing activities (242,608) (727,709)
Net increase (decrease) in cash and cash equivalents 601,946 (146,328)
Effect of exchange rate changes on cash and cash equivalents (18,227) 3,418
Cash and cash equivalents, beginning of the period 602,562 570,721
Cash and cash equivalents, end of the period $ 1,186,281 $ 427,811